EcoR1 Capital, LLC
SAN FRANCISCO, CA · Quarter end: Sep 30, 2026 · Filed with SEC: Nov 16, 2026 · Open the SEC source ↗
Portfolio Return (1Y)——
Portfolio Value (AUM)Total value of the fund's US stock portfolio reported to the SEC.$2.03B2026 Q3+ $218.4M options (notional, not included)
Positions36
Top-10 ConcentrationPercent of the portfolio in the 10 largest holdings. High means the fund is concentrated in few stocks.83.1%
What Changed This Quarter?
Top Holdings
ZYME
Zymeworks
27.0%
ANAB
Anaptysbio
17.6%
BMYCALL
Bristol Myers Squibb
9.7%
CGON
CG Oncology
5.9%
ETON
Eton Pharmaceuticals
5.6%
TRAX
First Tracks Biotherapeutics
5.0%
AKTS
Aktis Oncology
4.2%
CRSP
CRISPR Therapeutics
3.4%
New / Increased
10 new · 8 increased
BMYCALLNEW
Bristol-Myers Squibb
9.7%
ANRONEW
Alto Neuroscience
2.5%
Attovia Thera…NEW
Attovia Therapeutics
1.5%
ADRXNEW
Adarx Pharmaceuticals
1.0%
ETRANEW
Electra Therapeutics
0.8%
ERAS
Erasca
1.9%
+793.9%
CGON
CG Oncology
5.9%
+25.3%
ETON
Eton Pharmaceuticals
5.6%
+13.8%
Reduced / Exited
4 reduced · 7 sold out
ORIC
Oric Pharmaceuticals
1.8%
-55.0%
CGONCALL
CG Oncology
0.0%
-100.0%
BBOT
Bridgebio Oncology Therapeut
0.2%
-68.5%
ZURA
Zura Bio
0.1%
-42.4%
LEGNEXIT
Legend Biotech
1.1%
MBXEXIT
MBX Biosciences
1.0%
RLAYEXIT
Relay Therapeutics
0.6%
PHATEXIT
Phathom Pharmaceuticals
0.3%
Read the 2026-Q2 quarterly report · 13F Filing Calendar
13F data shows quarter-end positions, is delayed by up to 45 days and covers only long positions in US-listed securities; short positions, most derivatives and non-US assets are not reported.